Elixxer Ltd. (TSXV: ELXR.H) has entered into an amending agreement with AIP Asset Management Inc. and AIP Convertible Private Debt Fund L.P., effective June 30, 2026, restructuring key debt obligations as the company navigates financial difficulty. The agreement extends the maturity of $8,000,000 in outstanding secured notes, plus accrued interest, to December 31, 2026, and raises the ceiling on an unsecured promissory note to a maximum of $3,000,000. Because AIP is a control person of Elixxer, the transaction is classified as a related party transaction under applicable Canadian securities rules, a disclosure investors will want to review carefully.

Key Points

  • Elixxer Ltd. (TSXV: ELXR.H) announced an amending agreement with AIP Asset Management Inc. and AIP Convertible Private Debt Fund L.P.
  • The company extended the maturity date of $8,000,000 in secured notes, plus accrued interest, to December 31, 2026, and increased an unsecured promissory note to a maximum of $3,000,000.
  • The transaction is a related party transaction under MI 61-101; Elixxer is relying on exemptions from valuation and minority shareholder approval requirements.
  • Investors should watch for TSX Venture Exchange regulatory approval, which remains outstanding.

Debt Restructuring Terms and Effective Date

The amending agreement, carrying an effective date of June 30, 2026, modifies two distinct debt instruments. First, the maturity date on all issued and outstanding secured notes with a principal amount of $8,000,000, plus all accrued interest, has been extended to December 31, 2026. Second, the principal ceiling on an unsecured promissory note issued in favour of AIP Convertible Private Debt Fund L.P. has been raised to a maximum of $3,000,000. The company described these changes collectively as the "Amendments" and characterised them as measures designed to improve Elixxer's financial position.

Related Party Classification and MI 61-101 Exemptions

Because AIP holds control person status over Elixxer, the amending agreement and associated amendments constitute a related party transaction under TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101. The company disclosed it is relying on exemptions from both the formal valuation requirement and the minority shareholder approval requirement under sections 5.5(b) and 5.7(1)(e) of MI 61-101, citing that Elixxer is not listed on a specified market and is in financial difficulty. Elixxer also noted it did not file a material change report at least 21 days before executing the agreement, stating it considers that timeline reasonable given the circumstances.

Board Approval Process and Independent Director Oversight

The amending agreement was approved by independent members of Elixxer's board of directors — specifically, all directors other than Alexey (Alex) Kanayev and Jayahari (Jay) Balasubramaniam, who were excluded from the approval process given their connections to the counterparty. The release states no special committee was formed, and no materially contrary view or abstention was recorded among any director in relation to the transaction. Regulatory approval from the TSX Venture Exchange remains pending before the amendments take full effect.